Skip to Main Content

Author Details

Steven M Trifilio
Northwestern Memorial Hospital
2004
56
29
PMIDPaper TitleJournal TitlePublished Year
32659173Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation.J Oncol Pharm Pract2021
33179136The non-steroidal anti-inflammatory drug salsalate provides safe and effective control of mucositis-unrelated pain during autologous and allogeneic hematopoietic stem cell transplantation.Support Care Cancer2021
33575064Revisiting Infectious Complications Following Total Parenteral Nutrition Use During Hematopoietic Stem Cell Transplantation.J Adv Pract Oncol2020
33391852Aztreonam and Vancomycin for Initial Treatment of Febrile Neutropenia in Penicillin-Allergic Patients During Hematopoietic Stem Cell Transplantation.J Adv Pract Oncol2019
29080369Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.Clin Transplant2018
28719025Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.Am J Hematol2017
30333933Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies.J Adv Pract Oncol2017
28694084Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.Clin Lymphoma Myeloma Leuk2017
26838373Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.Bone Marrow Transplant2016
26524262Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.Bone Marrow Transplant2016
26758269Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Ann Hematol2016
25566825Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project.Drug Saf2015
26493022Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Clin Transplant2015
25648349Polymicrobial bacterial or fungal infections: incidence, spectrum of infection, risk factors, and clinical outcomes from a large hematopoietic stem cell transplant center.Transpl Infect Dis2015
25620386Amphotericin B deoxycholate nasal spray administered to hematopoietic stem cell recipients with prior fungal colonization of the upper airway passages is associated with low rates of invasive fungal infection.Transpl Infect Dis2015
25466707Economics of Malignant Gliomas: A Critical Review.J Oncol Pract2015
24850416Antimicrobial prophylaxis in hematopoietic stem cell transplantation recipients: 10 years after.Transpl Infect Dis2014
24786458Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.Blood2014
23106694Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique.Clin Transplant2013
23880719Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.Clin Adv Hematol Oncol2013
23814519Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.J Oncol Pract2013
24030903Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.J Clin Pharmacol2013
23768930Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.Leuk Res2013
23759246Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia.Leuk Res2013
23726414Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.Leuk Res2013
23480866Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.Expert Opin Drug Saf2013
23553448Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Drug Saf2013
23219779Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation.Biol Blood Marrow Transplant2013
22172465Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.Leuk Res2012
22430084Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation.Biol Blood Marrow Transplant2012
20974867Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.Antimicrob Agents Chemother2011
20818444Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.Bone Marrow Transplant2011
20086152Evaluation of a potential clinical interaction between ceftriaxone and calcium.Antimicrob Agents Chemother2010
19966844Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring.Bone Marrow Transplant2010
19223632Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.Antimicrob Agents Chemother2009
19636013Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?J Clin Oncol2009
18314434Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.JAMA2008
19038763Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.Lancet Oncol2008
16959316Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.Leuk Res2007
17563736Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.Bone Marrow Transplant2007
17533207Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.Arch Intern Med2007
17589527Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.Bone Marrow Transplant2007
17766662Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.Oncologist2007
17310132Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.Bone Marrow Transplant2007
17351937Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.Cancer2007
17408306Systematic review of piperacillin-induced neutropenia.Drug Saf2007
16708061Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.Bone Marrow Transplant2006
17054431Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.Br J Haematol2006
15654347Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.Bone Marrow Transplant2005
16131047Chemotherapy dosing in the setting of liver dysfunction.Oncology (Williston Park)2005
  • 1 - 50 of 56

Recommended Authors

Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 0
Molly Maloy
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Brad Moriyama
NIH Clinical Center
Career Start Year 2009
Number of shared co-authors 0
Shane J Cross
University of Tennessee Health Science Center
Career Start Year 2009
Number of shared co-authors 1
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 0
Geoffrey D E Cuvelier
University of Manitoba
Career Start Year 2005
Number of shared co-authors 0
Sung Won Choi
University of Michigan ann arbor
Career Start Year 2005
Number of shared co-authors 0
Kristin Baird
National Cancer Institute, National Institutes of Health
Career Start Year 2004
Number of shared co-authors 0
Laura F Newell
Oregon Health and Science University
Career Start Year 2003
Number of shared co-authors 1
Daanish Hoda
Loveland Clinic for Blood Cancer Therapy
Career Start Year 2003
Number of shared co-authors 1
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 1
Ivan Pasic
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Michiyo Sakiyama
the Lifestyle Related Disease Medical Center
Career Start Year 2000
Number of shared co-authors 0
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 2
Rachel J Cook
Oregon Health and Science University
Career Start Year 1997
Number of shared co-authors 1
Masahiro Kami
Medical Governance Research Institute
Career Start Year 1997
Number of shared co-authors 0
Leslie Lehmann
Dana Farber Cancer Institute/Boston Children's Hospital
Career Start Year 1996
Number of shared co-authors 0
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 3
Gabrielle Meyers
Oregon Health and Science University
Career Start Year 1994
Number of shared co-authors 1
Shmuel Shoham
Johns Hopkins School of Medicine, Johns Hopkins University
Career Start Year 1993
Number of shared co-authors 0
Paul L Martin
Duke University Medical Center
Career Start Year 1990
Number of shared co-authors 1
Joseph Schwartz
Icahn School of Medicine at Mount Sinai
Career Start Year 1990
Number of shared co-authors 0
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 4
Koen van Besien
University Hospitals of Cleveland
Career Start Year 1988
Number of shared co-authors 3
Steven Z Pavletic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1987
Number of shared co-authors 4
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 0
Coleman Rotstein
University of Toronto, and University Health Network, Toronto General Hospital
Career Start Year 1982
Number of shared co-authors 0
Dietger Niederwieser
University of Leipzig
Career Start Year 1982
Number of shared co-authors 2
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 2
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 3

Collaborators

June M McKoy
Feinberg School of Medicine, Northwestern University
Co-authored papers 18
Charles L Bennett
University of South Carolina
Co-authored papers 17
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 16
Dennis W Raisch
The University of New Mexico
Co-authored papers 14
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Co-authored papers 12
Dennis P West
Feinberg School of Medicine, Northwestern University
Co-authored papers 11
Paul R Yarnold
University of South Carolina College of Pharmacy
Co-authored papers 10
Steven M Belknap
Northwestern University Feinberg School of MedicineChicago
Co-authored papers 9
Timothy M Kuzel
548377Rush University Medical Center
Co-authored papers 8
Beatrice J Edwards
Central Texas Veterans Healthcare System
Co-authored papers 8
Athena T Samaras
Feinberg School of Medicine, Northwestern University
Co-authored papers 4
Daniel Mark Courtney
University of Texas Southwestern Medical Center
Co-authored papers 4
Cara Angelotta
Northwestern University, Feinberg School of Medicine
Co-authored papers 3
Jonathan R Nebeker
University of Utah
Co-authored papers 3
Benjamin Djulbegovic
Medical University of South Carolina
Co-authored papers 3
Cara C Tigue
McMaster University.
Co-authored papers 3
Al B Benson
Northwestern University Feinberg School of Medicine
Co-authored papers 2
David A Dorr
Department of Medical Informatics and Clinical Epidemiology
Co-authored papers 2
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 2
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 2
Sigmund A Weitzman
Northwestern University Feinberg School of Medicine
Co-authored papers 2
Scott C Howard
College of Nursing
Co-authored papers 2
Michael Henke
Medical Center, University of Freiburg
Co-authored papers 1
Jennifer Lagman
Co-authored papers 1
Rishi Sharma
Co-authored papers 1
John F Hurdle
University of Utah
Co-authored papers 1
Christina Georgopoulos
Co-authored papers 1
Denys T Lau
37345National Center for Health Statistics
Co-authored papers 1
Kathleen M Elverman
Co-authored papers 1
Kara J Gleason
Co-authored papers 1
Release 1.2